Literature DB >> 16163631

Endocarditis due to vancomycin-resistant enterococci: case report and review of the literature.

Michael P Stevens1, Michael B Edmond.   

Abstract

BACKGROUND: Endocarditis due to vancomycin-resistant enterococci (VRE) is rare, and the literature consists almost exclusively of reports of single cases.
METHODS: We report a case of VRE prosthetic valve endocarditis and review 18 cases of native and prosthetic valve VRE endocarditis reported in the literature.
RESULTS: The majority of cases were due to Enterococcus faecium. Nearly all of these infections were hospital acquired, and the vast majority of patients had significant underlying disease processes, including dialysis and transplantation. More than three-quarters of cases were left-sided, and the aortic valve was most commonly involved. Peripheral stigmata of endocarditis were not reported in any of the cases. Approximately 40% of patients developed cardiac complications. Nearly three-quarters of patients survived, despite the difficulties associated with providing bactericidal antimicrobial therapy, and only 4 patients underwent valve replacement.
CONCLUSIONS: VRE endocarditis is an uncommon nosocomial infection that affects patients with significant comorbid conditions. Most cases are due to E. faecium, and the aortic valve is involved in at least one-half of cases. One-third of patients require surgical treatment. Optimal antimicrobial therapy remains undefined, but an attempt to identify bactericidal combination therapy should be sought.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16163631     DOI: 10.1086/444459

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  17 in total

1.  Enterococcal endocarditis: can we win the war?

Authors:  Jose M Munita; Cesar A Arias; Barbara E Murray
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

Review 2.  Combination antibiotic therapy for the treatment of infective endocarditis due to enterococci.

Authors:  Sebastiano Leone; Silvana Noviello; Silvano Esposito
Journal:  Infection       Date:  2015-09-01       Impact factor: 3.553

3.  De novo daptomycin nonsusceptibility in a clinical isolate.

Authors:  Emil P Lesho; Glenn W Wortmann; David Craft; Kimberly A Moran
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

Review 4.  Daptomycin for the treatment of bacteraemia due to vancomycin-resistant enterococci.

Authors:  Jose M Munita; Barbara E Murray; Cesar A Arias
Journal:  Int J Antimicrob Agents       Date:  2014-09-02       Impact factor: 5.283

Review 5.  Vancomycin-resistant Enterococcus faecalis endocarditis: linezolid failure and strain characterization of virulence factors.

Authors:  Constantine Tsigrelis; Kavindra V Singh; Thais D Coutinho; Barbara E Murray; Larry M Baddour
Journal:  J Clin Microbiol       Date:  2006-12-20       Impact factor: 5.948

Review 6.  Management of multidrug-resistant enterococcal infections.

Authors:  C A Arias; G A Contreras; B E Murray
Journal:  Clin Microbiol Infect       Date:  2010-06       Impact factor: 8.067

7.  Endocarditis caused by resistant enterococcus: an overview.

Authors:  Katherine Reyes; Marcus Zervos
Journal:  Curr Infect Dis Rep       Date:  2013-08       Impact factor: 3.725

Review 8.  A potential role for daptomycin in enterococcal infections: what is the evidence?

Authors:  Rafael Cantón; Patricia Ruiz-Garbajosa; Ricardo L Chaves; Alan P Johnson
Journal:  J Antimicrob Chemother       Date:  2010-04-02       Impact factor: 5.790

9.  Impact of digestive and oropharyngeal decontamination on the intestinal microbiota in ICU patients.

Authors:  Robin F Benus; Hermie J Harmsen; Gjalt W Welling; Rob Spanjersberg; Jan G Zijlstra; John E Degener; Tjip S van der Werf
Journal:  Intensive Care Med       Date:  2010-03-16       Impact factor: 17.440

10.  Bioprosthetic Aortic Valve Endocarditis in Association with Enterococcus durans.

Authors:  Luca Fallavollita; Lorena Di Gioacchino; Fabrizio Balestrini
Journal:  Tex Heart Inst J       Date:  2016-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.